CNS Cancers Archives - Cancer Therapy Advisor

Novel Treatment Gains Accelerated Approval for Relapsed/Refractory Neuroblastoma

By

Steve Duffy

December 1, 2020

Approval was based on results from two phase 2 single-arm, open-label trials that demonstrated overall response rate and duration of response.

Brain Cancer

FDA Grants Orphan Drug Status to Berubicin for Malignant Gliomas

By

Brian Park, PharmD

June 16, 2020

he designation is supported by data from a phase 1 trial conducted by Reata Pharmaceuticals in 2016. Findings from the study showed 44% of patients treated with berubicin (n=11 out of 25) experienced a statistically significant improvement in progression free survival.

Radiosurgery and close monitoring is recommended to better preserve cognitive function in newly diag

Brain Cancer

Short Treatment Delays May Not Hamper Survival in Glioblastoma

By

Christina Bennett, MS

May 7, 2020

For patients with glioblastoma, short delays in the initiation of chemoradiotherapy after surgery were not linked to worse survival — yet initiation too soon was.

Brain Cancer

Pediatric Brain Cancer Outcomes Worse for Black, Hispanic Patients

April 30, 2020

Disparities for disease severity not seen at diagnosis, meaning postdiagnosis factors may affect outcome.

General Oncology

Pedmark Receives Priority Review for Prevention of Cisplatin-Induced Ototoxicity

By

Brian Park, PharmD

April 15, 2020

The application is supported by data from 2 pivotal open-label, randomized phase 3 trials (SIOPEL 6 and ACCL0431), which compared the efficacy of sodium thiosulfate plus cisplatin to cisplatin alone for the prevention of cisplatin-induced hearing loss.

Lymphoma

Autoimmune Conditions and Primary CNS Lymphoma Risk

By

C. Andrew Kistler, MD, PharmD

November 14, 2019

Primary central nervous system lymphoma (PCNSL) is a rare (incidence rate of 0.6 cases per 100,000 person years) non-Hodgkin lymphoma (NHL) found in the brain, spinal cord, and leptomeninges.

Childhood cancer survivors exposed to therapies that cause pulmonary dysfunction are associated with

ESMO 2019

Addition of Bevacizumab to Temozolomide-Based Chemotherapy Increased OR in Children With R/R Neuroblastoma

By

Susan Moench, PhD, PA-C

September 29, 2019

The addition of bevacizumab to temozolomide-based chemotherapy was also associated with higher rates of grade 3 or higher thrombocytopenia and anemia.

A review published in Blood highlights new approaches that are being investigated to treat PCNSL bas

Hematologic Cancers

Bing-Neel Syndrome: Managing Patients With Waldenström Macroglobulinemia Characterized by CNS Involvement

By

Susan Moench, PhD, PA-C

September 17, 2019

According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.

Administering bevacizumab before etoposide and cisplatin may be highly effective in patients with br

Head and Neck Cancer

Ribociclib Shown to Penetrate the Blood-Brain Barrier in Glioblastoma

By

Devona Williams, PharmD, BCOP

September 13, 2019

A phase 0 study of ribociclib in patients with recurrent glioblastoma seeks to inform the feasibility of the use of CDK 4/6 inhibitors for deadly brain tumors.

Chemotherapy treatment can affect a patient’s memory or attention span. It is often referred to as “chemo brain.” An individual may suffer from resulting short-term memory loss.8

Brain Cancer

Treatment Reduction in Intermediate-Risk Neuroblastoma Deemed Successful

By

Christina Bennett, MS

August 15, 2019

For specific subsets of patients with intermediate-risk neuroblastoma, an algorithm successfully reduced treatment while maintaining survival outcomes.